Biotech Growth Trust PLCLSE: BIOG

The Biotech Growth Trust PLC - Transaction in Own Shares

· Issued by Biotech Growth Trust PLC via PR Newswire

Summary by 6ix AI

The Biotech Growth Trust PLC bought 100,000 of its Ordinary shares of 25p each on October 16, 2026, at a price of 1373.18 pence per share, for cancellation.

Key details

  • The purchase was made under the authority granted at the company's Annual General Meeting held on July 16, 2026, which allows market purchases of up to an aggregate maximum of 2,864,231 of its own shares.
  • After this purchase, the company has 18,539,477 Ordinary shares in issue and the same number of voting rights; it holds no shares in treasury (shares bought back and kept by the company rather than cancelled).
  • Shareholders may use 18,539,477 as the denominator when working out whether they must notify their interest under the Financial Conduct Authority's (FCA, the UK financial regulator) Disclosure Guidance and Transparency Rules.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/the-biotech-growth-trust-plc-transaction-in-own-shares

                          For immediate release

16 October 2026

THE BIOTECH GROWTH TRUST PLC

(the "Company")

MARKET PURCHASE OF COMPANY'S OWN SHARES

Notification is given, pursuant to the authority granted at the Annual General
Meeting of the Company held on 16 July 2026 to make market purchases of the
Company's own shares up to an aggregate maximum of 2,864,231 that a market total
of 100,000 Ordinary shares of 25p each in the capital of the Company were
purchased today for cancellation by the Company at a price of 1373.18 pence per
share.

Following this transaction, the Company hereby notifies the market that the
total number of Ordinary shares that the Company has in issue, less the total
number of Ordinary shares bought back for cancellation by the Company following
such purchase, and therefore, the total number of voting rights in the Company
18,539,477. The Company does not currently hold any Ordinary shares in treasury.

The figure of 18,539,477 may be used by shareholders as the denominator for the
calculation by which they may determine if they are required to notify their
interest in, or change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.

For and on behalf of

Frostrow Capital LLP

Company Secretary

For further information, please contact:

Katherine Manson

Frostrow Capital LLP

Tel: 020 3709 8734


This information was brought to you by Cision http://news.cision.com

Biotech Growth Trust PLC on 6ix

Earlier from Biotech Growth Trust

All Biotech Growth Trust news releases